299 related articles for article (PubMed ID: 29804932)
1. Therapeutic Benefit of Autophagy Modulation in Pompe Disease.
Lim JA; Sun B; Puertollano R; Raben N
Mol Ther; 2018 Jul; 26(7):1783-1796. PubMed ID: 29804932
[TBL] [Abstract][Full Text] [Related]
2. Autophagy and lysosomes in Pompe disease.
Fukuda T; Roberts A; Ahearn M; Zaal K; Ralston E; Plotz PH; Raben N
Autophagy; 2006; 2(4):318-20. PubMed ID: 16874053
[TBL] [Abstract][Full Text] [Related]
3. Fiber type conversion by PGC-1α activates lysosomal and autophagosomal biogenesis in both unaffected and Pompe skeletal muscle.
Takikita S; Schreiner C; Baum R; Xie T; Ralston E; Plotz PH; Raben N
PLoS One; 2010 Dec; 5(12):e15239. PubMed ID: 21179212
[TBL] [Abstract][Full Text] [Related]
4. Improved efficacy of a next-generation ERT in murine Pompe disease.
Xu S; Lun Y; Frascella M; Garcia A; Soska R; Nair A; Ponery AS; Schilling A; Feng J; Tuske S; Valle MCD; Martina JA; Ralston E; Gotschall R; Valenzano KJ; Puertollano R; Do HV; Raben N; Khanna R
JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30843882
[TBL] [Abstract][Full Text] [Related]
5. Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease.
Fukuda T; Ahearn M; Roberts A; Mattaliano RJ; Zaal K; Ralston E; Plotz PH; Raben N
Mol Ther; 2006 Dec; 14(6):831-9. PubMed ID: 17008131
[TBL] [Abstract][Full Text] [Related]
6. Autophagy in skeletal muscle: implications for Pompe disease.
Shea L; Raben N
Int J Clin Pharmacol Ther; 2009; 47 Suppl 1(Suppl 1):S42-7. PubMed ID: 20040311
[TBL] [Abstract][Full Text] [Related]
7. Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder--murine Pompe disease.
Raben N; Schreiner C; Baum R; Takikita S; Xu S; Xie T; Myerowitz R; Komatsu M; Van der Meulen JH; Nagaraju K; Ralston E; Plotz PH
Autophagy; 2010 Nov; 6(8):1078-89. PubMed ID: 20861693
[TBL] [Abstract][Full Text] [Related]
8. Pompe Disease: New Developments in an Old Lysosomal Storage Disorder.
Meena NK; Raben N
Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32962155
[TBL] [Abstract][Full Text] [Related]
9. Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease.
Yi H; Sun T; Armstrong D; Borneman S; Yang C; Austin S; Kishnani PS; Sun B
J Mol Med (Berl); 2017 May; 95(5):513-521. PubMed ID: 28154884
[TBL] [Abstract][Full Text] [Related]
10. Failure of Autophagy in Pompe Disease.
Do H; Meena NK; Raben N
Biomolecules; 2024 May; 14(5):. PubMed ID: 38785980
[TBL] [Abstract][Full Text] [Related]
11. Restoration of muscle functionality by genetic suppression of glycogen synthesis in a murine model of Pompe disease.
Douillard-Guilloux G; Raben N; Takikita S; Ferry A; Vignaud A; Guillet-Deniau I; Favier M; Thurberg BL; Roach PJ; Caillaud C; Richard E
Hum Mol Genet; 2010 Feb; 19(4):684-96. PubMed ID: 19959526
[TBL] [Abstract][Full Text] [Related]
12. Impaired autophagy contributes to muscle atrophy in glycogen storage disease type II patients.
Nascimbeni AC; Fanin M; Masiero E; Angelini C; Sandri M
Autophagy; 2012 Nov; 8(11):1697-700. PubMed ID: 22940840
[TBL] [Abstract][Full Text] [Related]
13. Reduction of Autophagic Accumulation in Pompe Disease Mouse Model Following Gene Therapy.
McCall AL; Stankov SG; Cowen G; Cloutier D; Zhang Z; Yang L; Clement N; Falk DJ; Byrne BJ
Curr Gene Ther; 2019; 19(3):197-207. PubMed ID: 31223086
[TBL] [Abstract][Full Text] [Related]
14. Suppression of autophagy in skeletal muscle uncovers the accumulation of ubiquitinated proteins and their potential role in muscle damage in Pompe disease.
Raben N; Hill V; Shea L; Takikita S; Baum R; Mizushima N; Ralston E; Plotz P
Hum Mol Genet; 2008 Dec; 17(24):3897-908. PubMed ID: 18782848
[TBL] [Abstract][Full Text] [Related]
15. Modulation of mTOR signaling as a strategy for the treatment of Pompe disease.
Lim JA; Li L; Shirihai OS; Trudeau KM; Puertollano R; Raben N
EMBO Mol Med; 2017 Mar; 9(3):353-370. PubMed ID: 28130275
[TBL] [Abstract][Full Text] [Related]
16. Role of autophagy in the pathogenesis of Pompe disease.
Raben N; Roberts A; Plotz PH
Acta Myol; 2007 Jul; 26(1):45-8. PubMed ID: 17915569
[TBL] [Abstract][Full Text] [Related]
17. Akt inactivation induces endoplasmic reticulum stress-independent autophagy in fibroblasts from patients with Pompe disease.
Nishiyama Y; Shimada Y; Yokoi T; Kobayashi H; Higuchi T; Eto Y; Ida H; Ohashi T
Mol Genet Metab; 2012 Nov; 107(3):490-5. PubMed ID: 23041259
[TBL] [Abstract][Full Text] [Related]
18. Murine muscle cell models for Pompe disease and their use in studying therapeutic approaches.
Takikita S; Myerowitz R; Zaal K; Raben N; Plotz PH
Mol Genet Metab; 2009 Apr; 96(4):208-17. PubMed ID: 19167256
[TBL] [Abstract][Full Text] [Related]
19. Adjunctive β2-agonist treatment reduces glycogen independently of receptor-mediated acid α-glucosidase uptake in the limb muscles of mice with Pompe disease.
Farah BL; Madden L; Li S; Nance S; Bird A; Bursac N; Yen PM; Young SP; Koeberl DD
FASEB J; 2014 May; 28(5):2272-80. PubMed ID: 24448824
[TBL] [Abstract][Full Text] [Related]
20. Suppression of mTORC1 activation in acid-α-glucosidase-deficient cells and mice is ameliorated by leucine supplementation.
Shemesh A; Wang Y; Yang Y; Yang GS; Johnson DE; Backer JM; Pessin JE; Zong H
Am J Physiol Regul Integr Comp Physiol; 2014 Nov; 307(10):R1251-9. PubMed ID: 25231351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
